Most cited papers from Eisai (Japan)

Eisai (Japan)

What are the most cited papers from Eisai (Japan)?

The most cited paper from Eisai (Japan) is "MassBank: a public repository for sharing mass spectral data for life sciences" (Hisayuki Horai et al., 2010), with 2,595 citations. Next come "Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein" (2,108) and "Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction" (1,974).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 286 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	MassBank: a public repository for sharing mass spectral data for life sciences Hisayuki Horai et al. · Journal of Mass Spectrometry Open access	Jul 2010	2,595
2	Exponentially Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in Proteomics by the Number of Sequenced Peptides per Protein Yasushi Ishihama, Yoshiya Oda, Tsuyoshi Tabata et al. · Molecular & Cellular Proteomics Open access	15 Jun 2005	2,108
3	Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction Jesse C. Chow, Donna W. Young, Douglas Taylor Golenbock et al. · Journal of Biological Chemistry Open access	Apr 1999	1,974
4	Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Richard S. Finn, Masafumi Ikeda, Andrew Xiuxuan Zhu et al. · Journal of Clinical Oncology Open access	27 Jul 2020	1,188
5	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study Javier Cortés, Joyce O’Shaughnessy, David M. Loesch et al. · The Lancet	Mar 2011	1,110
6	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial Robert John Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology Open access	25 Oct 2015	957
7	Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis Steven M. Opal et al. · JAMA Open access	20 Mar 2013	813
8	A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death Jonathan Ham, Carol Babij, Jonathan Richard Whitfield et al. · Neuron Open access	May 1995	796
9	Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome Yoshiya Oda, Takeshi Nagasu, Brian T. Chait · Nature Biotechnology	Apr 2001	780
10	The Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial Sharon L. Rogers, Lawrence T. Friedhoff · Dementia and Geriatric Cognitive Disorders	1996	743
11	The β-Secretase BACE1 in Alzheimer’s Disease Harald Juergen Hampel et al. · Biological Psychiatry Open access	12 Feb 2020	695
12	Splicing factor SF3b as a target of the antitumor natural product pladienolide Yoshihiko Kotake, Koji Sagane, Takashi Owa et al. · Nature Chemical Biology Open access	22 Jul 2007	675
13	cDNA Cloning of the Hepatocyte Canalicular Isoform of the Multidrug Resistance Protein, cMrp, Reveals a Novel Conjugate Export Pump Deficient in Hyperbilirubinemic Mutant Rats Markus Wolfgang Büchler, Jörg König, Manuela Brom et al. · Journal of Biological Chemistry Open access	Jun 1996	650
14	Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study Motoko Yamaguchi, Yok‐Lam Kwong, Won Seog Kim et al. · Journal of Clinical Oncology	12 Oct 2011	608
15	E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition Junji Matsui, Yuji Yamamoto, Yasuhiro Funahashi et al. · International Journal of Cancer	17 Oct 2007	555
16	Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase Junji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka et al. · Clinical Cancer Research Open access	Sep 2008	536
17	Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma Sarah K. Knutson et al. · Molecular Cancer Therapeutics	22 Feb 2014	531
18	On The Rate and Extent of Drug Delivery to the Brain Margareta Hammarlund‐Udenaes, Markus Fridén, Stina Syvänen et al. · Pharmaceutical Research Open access	5 Dec 2007	521
19	γ-Secretase: Successive Tripeptide and Tetrapeptide Release from the Transmembrane Domain of β-Carboxyl Terminal Fragment Mako Takami, Yu Nagashima, Y Sano et al. · Journal of Neuroscience Open access	14 Oct 2009	519
20	Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage Yuji Yamamoto et al. · Vascular Cell Open access	2014	506
21	Defects of urogenital development in mice lacking Emx2 Norimasa Miyamoto, Michio Yoshida, Shigeru Kuratani et al. · Development	May 1997	488
22	Accelerating effects of chitosan for healing at early phase of experimental open wound in dogs Hiroshi Ueno, Haruo YAMADA, Ichiro Tanaka et al. · Biomaterials	Aug 1999	486
23	Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models Osamu Tohyama, Junji Matsui, Kotaro Kodama et al. · Journal of Thyroid Research Open access	2014	483
24	Adjunctive perampanel for refractory partial-onset seizures Jacqueline A. French et al. · Neurology Open access	27 Jul 2012	480
25	Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE Open access	27 Feb 2019	471
26	Molecular and Functional Characterization of a Novel Mouse Transient Receptor Potential Protein Homologue TRP7 Takaharu Okada, Ryuji Inoue, Kazuto Yamazaki et al. · Journal of Biological Chemistry Open access	Sep 1999	462
27	Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond Wesley C. Van Voorhis et al. · PLoS Pathogens Open access187 authors	28 Jul 2016	452
28	Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole Ishizaki, Horai · Alimentary Pharmacology & Therapeutics Open access	Aug 1999	429
29	Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305 Jacqueline A. French, Gregory L. Krauss, Bernhard Jochen Steinhoff et al. · Epilepsia	20 Aug 2012	429
30	The TLR4 antagonist Eritoran protects mice from lethal influenza infection Kari Ann Shirey, Wendy Lai, Alison J. Scott et al. · Nature Open access	May 2013	424
31	Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy Takahisa Hanada, Yutaka Hashizume, Naoki Tokuhara et al. · Epilepsia	2 Jun 2011	419
32	Selective degradation of splicing factor CAPERα by anticancer sulfonamides Taisuke Uehara, Yukinori Minoshima, Koji Sagane et al. · Nature Chemical Biology	24 Apr 2017	404
33	Circulating miRNA Biomarkers for Alzheimer's Disease Pavan Kumar, Zoltán Dezső, Crystal MacKenzie et al. · PLoS ONE Open access	29 Jul 2013	387
34	International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment Ksenia Blinova et al. · Cell Reports Open access	Sep 2018	382
35	Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia Eric Wang et al. · Cancer Cell Open access	23 Feb 2019	381
36	Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Harumi Takahashi, Grant R. Wilkinson, Edith A. Nutescu et al. · Pharmacogenetics and Genomics Open access	Feb 2006	375
37	NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018 Robert I. Haddad et al. · Journal of the National Comprehensive Cancer Network	Dec 2018	372
38	A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting Pierre N. Tariot, Jeffrey L. Cummings, Ira R. Katz et al. · Journal of the American Geriatrics Society	Dec 2001	370
39	Emx1 and Emx2 functions in development of dorsal telencephalon Michio Yoshida, Yoko Suda, Isao Matsuo et al. · Development	1997	369
40	Glutamate release and neuronal damage in ischemia Yukio Nishizawa · Life Sciences	Jun 2001	368
41	Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states Takeshi Yoshida, Yoichi Ozawa, Takayuki Kimura et al. · British Journal of Cancer Open access	25 Feb 2014	363
42	Effects of chitin and its derivatives on the proliferation and cytokine production of fibroblasts in vitro Takashi Mori, Masahiro Okumura, Mitsunobu Matsuura et al. · Biomaterials	Jul 1997	355
43	Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science Open access	16 Nov 2018	350
44	Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe et al. · Journal of Gastroenterology Open access	4 Oct 2016	346
45	Synthesis and Structure-Activity Relationships of Acetylcholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds Hachiro Sugimoto, Youichi Iimura, Yoshiharu Yamanishi et al. · Journal of Medicinal Chemistry Open access	Nov 1995	342
46	Discovery of Novel Antitumor Sulfonamides Targeting G1 Phase of the Cell Cycle Takashi Owa, Hiroshi Yoshino, Tatsuo Okauchi et al. · Journal of Medicinal Chemistry	26 Aug 1999	330
47	Donepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors Hachiro Sugimoto, Y. Yamanish, Youichi Iimura et al. · Current Medicinal Chemistry	Mar 2000	325
48	E5531, a Pure Endotoxin Antagonist of High Potency William J. Christ et al. · Science	7 Apr 1995	324
49	Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial Kōichi Goto et al. · Journal of Clinical Oncology Open access	11 Sep 2023	323
50	Tumor Deposits in Colorectal Cancer: Improving the Value of Modern Staging—A Systematic Review and Meta-Analysis Irıs D. Nagtegaal, Nikki Knijn, Niek Hugen et al. · Journal of Clinical Oncology ReviewOpen access	23 Feb 2017	320

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.